Prognostic value of MTSS1 gene expression on acute leukemia patients outcome.
Biomark Med
; 17(21): 889-898, 2023 11.
Article
em En
| MEDLINE
| ID: mdl-38230972
ABSTRACT
Background:
This study aimed to evaluate the prognostic value of the MTSS1 gene expression in patients with acute leukemia. Patients &methods:
MTSS1 gene expression was quantified in 120 newly diagnosed acute leukemia patients, by quantitative reverse transcription PCR at diagnosis and after induction chemotherapy therapy.Results:
Baseline MTSS1 gene expression was significantly higher in acute leukemia patients compared to the control group (p < 0.001). Acute leukemia patients with low baseline MTSS1 gene expression at diagnosis have significantly shorter overall survival and disease-free survival compared with those with higher expression (p < 0.001 for both).Conclusion:
Downregulation of MTSS1 gene expression at diagnosis was associated with poor outcome in either cytogenetic acute myeloid leukemia or B-cell acute lymphoblastic leukemia.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Leucemia Mieloide Aguda
/
Regulação Leucêmica da Expressão Gênica
Tipo de estudo:
Diagnostic_studies
/
Prognostic_studies
Limite:
Humans
Idioma:
En
Revista:
Biomark Med
Assunto da revista:
BIOQUIMICA
/
MEDICINA
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Egito